CVRx cuts revenue outlook as analysts reset targets for CVRx stock

Published on 10/21/2026 at 02:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 16.00 percent to USD 15.70 million on October 12, 2026. For CVRx stock, 2026 revenue guidance is USD 58.00-60.00 million.

Revenue outlook and upcoming date

CVRx lowered its 2026 revenue outlook to USD 58.00-60.00 million on October 12, 2026.
Second-quarter revenue rose 16.00 percent to USD 15.70 million.
MarketBeat lists November 4, 2026 as CVRx's next estimated earnings date.

CVRX, US1266381052, Illustration mit AI erstellt.

CVRx cuts its 2026 revenue outlook to USD 58.00-60.00 million, while CVRx stock remains tied to the company's sales execution. In its October 12, 2026 earnings-call transcript, Benzinga reported that management lowered its full-year outlook after a weaker expected second half.

Why guidance changed

CVRx generated USD 15.70 million in second-quarter 2026 revenue, up 16.00 percent from the prior-year quarter. Gross profit reached USD 13.70 million, and gross margin increased to 87.00 percent, according to Benzinga.

The same transcript said CVRx's net loss narrowed to USD 14.00 million from USD 14.70 million in the year-earlier quarter. Cash and cash equivalents stood at USD 64.60 million on June 30, 2026, while operating and investing cash use totaled USD 8.90 million during the quarter.

What does the outlook mean?

Management attributed the reset to salesforce productivity problems in regions with high turnover and new leadership, alongside reimbursement pressure from a large Medicare Advantage payer. About 60.00 percent of quota-carrying US territory managers had joined during the previous 18 months, making onboarding and training a central operating issue.

The company also guided to third-quarter 2026 revenue of USD 13.50-14.50 million, full-year gross margin of 86.00-87.00 percent and operating expenses of USD 99.00-101.00 million. These figures frame the central investor test: whether better execution can convert strong gross margins into narrower losses.

Analyst target and next date

On September 22, 2026, Investing.com reported that Canaccord Genuity reiterated a Buy rating and a USD 5.00 price target. The same report said Piper Sandler cut its target from USD 12.00 to USD 4.00 and Cantor Fitzgerald reduced its target from USD 13.00 to USD 5.00 after the guidance reset.

MarketBeat lists November 4, 2026 as the next estimated earnings date. That report also puts the consensus price target at USD 4.30, leaving execution and reimbursement as the measurable themes for the next update.

The stock's market frame

CVRx was last quoted at USD 1.39 on October 20, 2026 at 4:00 p.m. ET on Nasdaq, according to the finance quote. Its 52-week range was USD 1.25 to USD 11.30, and its market capitalization was USD 37.0 million on that date. The company describes its business as developing baroreceptor neuromodulation therapies for cardiovascular disease through its investor-relations materials at CVRx.